Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04871919 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis

Study acronym: FILOSOPHY
StatusActive, Not Recruiting
PhaseNot specified
Started2021-05-11
View on ClinicalTrials.gov ↗

Amendment history

2025-09-09
Study Status v27
Re-verified, no change to tracked fields
2024-12-13
Study Status, Outcome Measures v26
Secondary endpointsdetails revised at 7 of 7 entries
2024-07-26
Study Identification, Study Status, Sponsor/Collaborators, Contacts/Locations v25
Primary completion date2025-07→2028-06
Completion date2025-07→2028-06
Lead sponsorLakefront Biotherapeutics NV→Alfasigma S.p.A.
2024-05-14
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v24
Trial statusRecruiting→Active, Not Recruiting
Enrollment targetestimated 1500→confirmed 1304
Study sites99→89
2024-04-08
Study Identification, Study Status, Contacts/Locations v23
Study sitesdetails revised at 2 of 99 sites
Show 22 earlier versions
2024-01-09
Study Status, Contacts/Locations v22
Study sitesdetails revised at 2 of 99 sites
2023-04-17
Study Status, Contacts/Locations v21
Study sitesdetails revised at 2 of 99 sites
2023-02-13
Study Status, Contacts/Locations v20
Study sites98→99
2023-01-12
Study Status, Contacts/Locations v19
Study sites97→98
2022-12-08
Study Status, Contacts/Locations v18
Study sites95→97
2022-10-13
Study Status, Contacts/Locations v17
Study sites94→95
2022-08-11
Study Status, Contacts/Locations v16
Study sites93→94
2022-07-26
Study Status, Outcome Measures, Contacts/Locations v15
Study sites90→93
Secondary endpoints5 to 7 entries
medication adherence, compliance questionnaire rheumatology 5 (CQR5) patients' assessment of Rheumatoid Arthritis Impact of Disease (RAID)
2022-06-13
Study Status, Contacts/Locations v14
Study sites85→90
2022-05-13
Study Status, Contacts/Locations v13
Study sites81→85
2022-04-19
Study Status, Contacts/Locations v12
Study sites73→81
2022-03-21
Study Status, Contacts/Locations v11
Study sites67→73
2022-02-17
Study Status, Contacts/Locations v10
Study sites57→67
2022-01-24
Study Status, Contacts/Locations v9
Study sites44→57
2021-12-01
Study Status, Contacts/Locations v8
Study sites36→44
2021-11-04
Study Status, Contacts/Locations v7
Study sites33→36
2021-10-06
Study Status, Contacts/Locations v6
Study sites24→33
2021-09-09
Study Status, Contacts/Locations v5
Study sites17→24
2021-08-12
Study Status, Contacts/Locations v4
Study sites13→17
2021-07-13
Study Status, Contacts/Locations v3
Study sites7→13
2021-06-21
Study Status, Contacts/Locations v2
Study sites3→7
2021-05-19
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2021-05→confirmed 2021-05-11
Study sitesdetails revised at 3 of 3 sites
2021-04-29
Original filing
An observational study to describe the effectiveness, safety, and patient-reported outcomes in patients with moderate to severe active rheumatoid arthritis (RA) receiving filgotinib in real-world setting.
Trial Details
NCT Number NCT04871919
Lead Sponsor Alfasigma S.p.A.
Conditions Rheumatoid Arthritis
Enrollment 1,304 participants
Start Date 2021-05-11
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2025-09-15